Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Who’ll buy uniQure now?

Even without its lead hemophilia program, the gene therapy company could make for an attractive takeout target

June 27, 2020 1:46 AM UTC

UniQure’s out-licensing deal for its lead gene therapy program in hemophilia B may have disappointed investors, but that does not preclude the Dutch company from remaining an attractive takeout target.

Investors immediately soured on Wednesday’s deal in which uniQure N.V. (NASDAQ:QURE) granted CSL Ltd. (ASX:CSL) exclusive, worldwide rights to etranacogene dezaparvovec. UniQure’s shares fell 22% on Thursday, the first trading session after the deal was announced...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article